Brian Steg, MD
Cardiovascular Disease · Conover, NCNPI 1821050782
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,514 and has fallen 97.9% since, to $32 in 2025.
Across 174 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$495
- Johnson & Johnson$412
- Abbott$299
- Novartis$283
- Medtronic$271
- Pfizer$189
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,05799%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 33 | $495 |
| Johnson & Johnson | 27 | $412 |
| Abbott | 10 | $299 |
| Novartis | 19 | $283 |
| Medtronic(2 entities) | 10 | $271 |
| Pfizer | 12 | $189 |
| AstraZeneca | 10 | $139 |
| E.r. Squibb & Sons, L.L.C. | 8 | $119 |
| Chiesi USA, Inc. | 7 | $111 |
| Cardinal Health 200 LLC | 1 | $89 |
| Sanofi-aventis U.S. LLC | 5 | $65 |
| Penumbra, Inc. | 1 | $65 |
| Merck | 3 | $48 |
| Portola Pharmaceuticals, LLC | 3 | $47 |
| Irhythm Technologies, Inc. | 3 | $40 |
| Bardy Diagnostics, Inc. | 1 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $36 |
| Boehringer Ingelheim | 2 | $36 |
| Scpharmaceuticals Inc. | 1 | $35 |
| Astellas Pharma US Inc | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $31 |
| Boston Scientific | 2 | $29 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $24 |
| Abiomed | 1 | $22 |
| Cook Medical LLC | 1 | $20 |
| Nuwellis, Inc. | 1 | $18 |
| Biotronik Inc. | 1 | $18 |
| Elutia, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| Bayer | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$131
How this compares
$3,081 in reported general payments places this provider in the 55th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Conover
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Michael RinaldiCharlotte$722K
- Markus SchererCharlotte$526K
- Robert MentzDurham$489K
- Sean PokorneyMorganton$477K
- Adrian HernandezDurham$409K
- Sanjeev GulatiCharlotte$406K
- Richard BrowneCharlotte$379K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.